These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11025 related articles for article (PubMed ID: 15603188)

  • 1. Recombinant cancer vaccines based on viral vectors.
    Moingeon P
    Dev Biol (Basel); 2004; 116():117-22; discussion 133-43. PubMed ID: 15603188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
    van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
    Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
    Trakatelli M; Toungouz M; Lambermont M; Heenen M; Velu T; Bruyns C
    Cancer Gene Ther; 2005 Jun; 12(6):552-9. PubMed ID: 15665821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccines against melanoma and colorectal cancer.
    Tartaglia J; Bonnet MC; Berinstein N; Barber B; Klein M; Moingeon P
    Vaccine; 2001 Mar; 19(17-19):2571-5. PubMed ID: 11257394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor vaccines: conception, development and evaluation in humans].
    Moingeon P
    Ann Pharm Fr; 2002 Jul; 60(4):253-9. PubMed ID: 12378152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.
    Tine JA; Firat H; Payne A; Russo G; Davis SW; Tartaglia J; Lemonnier FA; Demoyen PL; Moingeon P
    Vaccine; 2005 Jan; 23(8):1085-91. PubMed ID: 15620483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.
    Poulet H; Minke J; Pardo MC; Juillard V; Nordgren B; Audonnet JC
    Vaccine; 2007 Jul; 25(30):5606-12. PubMed ID: 17227690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
    Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
    Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of antigen-specific immune responses induced by canarypox virus vaccines.
    Bos R; van Duikeren S; van Hall T; Lauwen MM; Parrington M; Berinstein NL; McNeil B; Melief CJ; Verbeek JS; van der Burg SH; Offringa R
    J Immunol; 2007 Nov; 179(9):6115-22. PubMed ID: 17947686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
    Riezebos-Brilman A; de Mare A; Bungener L; Huckriede A; Wilschut J; Daemen T
    J Clin Virol; 2006 Mar; 35(3):233-43. PubMed ID: 16448844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
    van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
    J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
    Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J
    Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus.
    Karanikas V; Lurquin C; Colau D; van Baren N; De Smet C; Lethé B; Connerotte T; Corbière V; Demoitié MA; Liénard D; Dréno B; Velu T; Boon T; Coulie PG
    J Immunol; 2003 Nov; 171(9):4898-904. PubMed ID: 14568971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
    Hodge JW; McLaughlin JP; Kantor JA; Schlom J
    Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).
    Jourdier TM; Moste C; Bonnet MC; Delisle F; Tafani JP; Devauchelle P; Tartaglia J; Moingeon P
    Gene Ther; 2003 Dec; 10(26):2126-32. PubMed ID: 14625567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.
    Paillot R; Kydd JH; Sindle T; Hannant D; Edlund Toulemonde C; Audonnet JC; Minke JM; Daly JM
    Vet Immunol Immunopathol; 2006 Aug; 112(3-4):225-33. PubMed ID: 16621023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant viral vectors: cancer vaccines.
    Harrop R; John J; Carroll MW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):931-47. PubMed ID: 17030074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 552.